GALT — Galectin Therapeutics Share News
0.000.00%
Last trade - 00:00- $340.87m
- $465.30m
Brief: Galectin Therapeutics Inc Files For Mixed Shelf Offering Of Up To $100 Million - SEC Filing
Brief: Galectin Therapeutics Reports 2022 Loss Per Share Of $0.65
Galectin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Galectin Therapeutics Reports 2022 Net Loss Of $0.65 Per Share
Galectin Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Galectin Therapeutics Reports Positive Outcome Of Its Third Data And Safety Monitoring Board Meeting For Navigate
Brief: Galectin Therapeutics Final Randomization Status Of Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Cirrhosis Patients
Brief: Galectin Therapeutics Ends Enrollment Of Navigate, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin
Brief: Galectin Therapeutics Reports Financial Results For The Quarter Ended September 30, 2022 And Provides Business Update
Galectin Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Galectin Therapeutics Inc Posts Qtrly Loss Per Share of $0.14
Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Galectin gains after FDA nod for cancer therapy trial
Brief: Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
Brief: Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
Galectin up on positive review from meeting for lead drug's trial
Brief: Galectin Therapeutics Reports The Positive Outcome Of The Second Data And Safety Monitoring Board Meeting For Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Brief: Galectin Therapeutics Reports The Positive Outcome Of The Second Data And Safety Monitoring Board Meeting For Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Galectin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary